RGT-61159
RGT-61159 Phase 3 (planned, not yet registered)
Rgenta Therapeutics · Phase 3 · Not yet recruiting · Enrollment 150
| Arm | Reported safety |
|---|---|
| RGT-61159 84 mg + best supportive care | n/r |
| RGT-61159 60 mg + best supportive care | n/r |
| Placebo + best supportive care | n/r |
A count stays a count. This page does not turn a count into a percent.